Posted by Michael Wonder on 15 May 2018
FDA to name companies accused of hindering generic drug development
14 May 2018 - On Thursday, the FDA plans to start publishing the names of pharmaceutical companies that have been accused of withholding samples of drugs from generic manufacturers.
This is part of the Trump administration’s broader plan to bring down drug prices by fostering competition. In a speech Monday, Secretary of Health and Human Services Alex Azar highlighted this forthcoming action by the FDA as one way to “call out the manufacturers who may be abusing the rules that built our free market for drugs.”
